Dose-Blinded Myosin Inhibition in Patients with Obstructive HCM Referred for Septal Reduction Therapy: Outcomes Through 32-Weeks.
Milind Y DesaiAnjali Tiku OwensJeffrey B GeskeKathy WolskiSara SaberiAndrew WangMark V SherridPaul C CremerSrihari S NaiduNicholas G SmediraHartzell V SchaffEllen McErleanChristina SewellAarthi BalasubramanyamKathy LamplAmy J SehnertSteven E NissenPublished in: Circulation (2022)
URL: Clinicaltrials.gov Unique Identifier: NCT04349072.